Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aethlon Medical, Inc. AEMD

Healthcare  —  Medical Devices
6.28 (0.49) (7.24%) as of 25 Sep
Market cap
$10.4M
P/E
0.0×
Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Analyst’s Commentary of Aethlon Medical, Inc. (AEMD) Performance

Updated

Aethlon Medical, Inc. (AEMD) presents a complex financial picture characterized by significant volatility and challenges in achieving profitability. Over the past decade, the company has experienced substantial fluctuations in its financial metrics, reflecting both the inherent risks and potential opportunities within its business model.

Historical Financial Performance

Revenue and Profitability

Aethlon Medical’s revenue trajectory has been inconsistent, with notable fluctuations over the years. In 2015, the company reported revenue of approximately $762,400, which decreased significantly to $149,600 by 2018, marking a decline of about 80%. However, revenue rebounded to $574,200 in 2023, representing a 284% increase from 2018. Despite these revenue fluctuations, the company’s gross margin has remained consistently at 1.0, indicating that the cost of goods sold has been effectively managed relative to sales.

The company’s earnings before taxes (EBT) have consistently been negative, with a notable increase in losses from $6,979,500 in 2015 to $12,029,800 in 2023. This trend highlights ongoing challenges in achieving profitability, with the EBT margin reflecting significant negative values, such as -38.1% in 2018 and -20.95% in 2023. These figures underscore the company’s struggle to convert revenue into profit, a critical concern for potential investors.

Cash Flow and Capital Expenditure

Aethlon Medical’s operational cash flow has also been negative throughout the period, with a notable increase in cash outflows from $5,049,400 in 2015 to $10,505,100 in 2023. This trend indicates a persistent reliance on external financing to sustain operations. Capital expenditures have been relatively modest, with a peak of $943,100 in 2023, suggesting a cautious approach to investment in fixed assets.

Balance Sheet Analysis

Debt and Equity

The company’s total debt has fluctuated, peaking at $1,209,000 in 2023. However, Aethlon Medical has maintained a negative net debt position, indicating that its cash reserves exceed its debt obligations. This is a positive indicator of financial health, as it suggests the company has a buffer to manage its liabilities.

Shareholders’ equity has shown significant growth, from $651,400 in 2015 to $15,064,200 in 2023, reflecting successful capital raises. However, the book value per share has decreased from $17.46 in 2015 to $7.33 in 2023, indicating dilution effects from increased shares outstanding, which rose from 37,300 in 2015 to 2,054,000 in 2023.

Market Performance and Valuation

Stock Price and Ratios

The most recent stock price of Aethlon Medical is approximately 0.7, aligning with the low end of analyst price targets. This price represents a significant decline from historical highs, reflecting market skepticism about the company’s future prospects. The price-to-sales (PS) ratio has varied widely, peaking at 84.39 in 2015 and dropping to 10.60 in 2023, suggesting a more conservative market valuation relative to sales.

Insider Transactions

Interestingly, there have been no insider transactions, either buys or sells, reported in the past year. This lack of insider activity could indicate a neutral stance from those closest to the company’s operations, neither signaling confidence nor concern.

Future Outlook

Analyst Predictions

Looking forward, analysts predict a challenging path for Aethlon Medical. The anticipated revenue for 2025 is approximately $533,300, a decrease from 2023 levels, suggesting potential headwinds in revenue generation. However, the company is expected to achieve a break-even EBT margin by 2025, which could signal a turning point towards profitability if managed effectively.

Price Targets

Analyst price targets for Aethlon Medical range from a low of 0.7 to a high of 7.0, with a mean target of 3.85. The current stock price is at the low end of this range, suggesting potential upside if the company can execute its strategic initiatives successfully.

Conclusion

Aethlon Medical, Inc. faces significant challenges in achieving consistent revenue growth and profitability. The company’s financial history reflects volatility and a reliance on external financing, with ongoing efforts to manage costs and improve operational efficiency. While the balance sheet shows a strong cash position relative to debt, the dilution of shares and negative earnings remain concerns.

The future outlook hinges on the company’s ability to stabilize revenue and achieve profitability, as indicated by analyst predictions. The current stock price suggests market caution, but the potential for upside exists if Aethlon Medical can deliver on its strategic goals. Investors should closely monitor the company’s progress in these areas, considering both the risks and opportunities inherent in its business model.